ZOLEDRONIC ACID (ZOL) IMPROVES DISEASE-FREE (DFS) AND RECURRENCE-FREE SURVIVAL (RFS) IN PREMENOPAUSAL WOMEN WITH EARLY BREAST CANCER (ERBC) RECEIVING ADJUVANT ENDOCRINE THERAPY: MULTIVARIATE ANALYSIS OF EFFICACY DATA FROM THE AUSTRIAN BREAST AND COLORECTAL CANCER STUDY GROUP (ABCSG)-12

被引：0
|
作者：
Gnant, M. [1 ]
Mlineritsch, B. [2 ]
Schippinger, W. [3 ]
Luschin-Ebengreuth, G. [3 ]
Steger, G. G. [4 ]
Bjelic-Radisic, V. [3 ]
Jakesz, R.
Kubista, E.
Marth, C. [5 ]
Greil, R. [2 ]
机构：
[1] Med Univ Vienna, Austrian Breast & Colorectal Canc Study Grp, Vienna, Austria
[2] Paracelsus Med Univ Salzburg, Salzburg, Austria
[3] Med Univ Graz, Graz, Austria
[4] Univ Vienna, Vienna, Austria
[5] Med Univ Innsbruck, Innsbruck, Austria
来源：
ANNALS OF ONCOLOGY | 2008年 / 19卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：44 / 44
页数：1
相关论文
共 26 条
  • [1] ADDITION OF ZOLEDRONIC ACID (ZOL) TO ADJUVANT ENDOCRINE THERAPY IMPROVES DISEASE-FREE (DFS) AND RECURRENCE-FREE SURVIVAL (RFS) IN PREMENOPAUSAL WOMEN WITH HORMONE-RESPONSIVE EARLY BREAST CANCER (HREBC): MULTIVARIATE ANALYSES OF THE AUSTRIAN BREAST AND COLORECTAL CANCER STUDY GROUP 12 (ABCSG-12) TRIAL
    Gnant, M.
    Mlineritsch, B.
    Schippinger, W.
    Luschin-Ebengreuth, G.
    Poestlberger, S.
    Menzel, C.
    Jakesz, R.
    Kubista, E.
    Marth, C.
    Greil, R.
    [J]. ANNALS OF ONCOLOGY, 2009, 20 : 30 - 30
  • [2] ADJUVANT ENDOCRINE THERAPY, ALONE OR IN COMBINATION WITH ZOLEDRONIC ACID (ZOL), IN PREMENOPAUSAL PATIENTS (PTS) WITH ENDOCRINE-RESPONSIVE EARLY BREAST CANCER (EBC): SUBGROUP ANALYSES OF ABCSG-12
    Gnant, M.
    Mlineritsch, B.
    Stoeger, H.
    Luschin-Ebengreuth, G.
    Poestlberger, S.
    Steger, G. G.
    Jakesz, R.
    Singer, C. F.
    Eidtmann, H.
    Greil, R.
    [J]. ANNALS OF ONCOLOGY, 2010, 21 : 79 - 79
  • [3] COST-EFFECTIVENESS OF ZOLEDRONIC ACID (ZOL) PLUS ENDOCRINE THERAPY (ET) IN PREMENOPAUSAL WOMEN WITH EARLY STAGE BREAST CANCER (BC) ENROLLED IN THE ABCSG-12 STUDY
    Gnant, M.
    Delea, T. E.
    Sofrygin, O.
    Kaura, S.
    [J]. ANNALS OF ONCOLOGY, 2009, 20 : 30 - 31
  • [4] Zoledronic acid prevents cancer treatment-induced bone loss in premenopausal women receiving adjuvant endocrine therapy for hormone-responsive breast cancer: A report from the Austrian Breast and Colorectal Cancer Study Group
    Gnant, Michael F. X.
    Mlineritsch, Brigitte
    Luschin-Ebengreuth, Gero
    Grampp, Stephan
    Kaessmann, Helmut
    Schmid, Marianne
    Menzel, Christian
    Piswanger-Soelkner, Jutta Claudia
    Galid, Arik
    Mittlboeck, Martina
    Hausmaninger, Hubert
    Jakesz, Raimund
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (07) : 820 - 828
  • [5] NUMBER NEEDED TO TREAT (NNT) AS A MEASURE OF ZOLEDRONIC ACID (ZOL) EFFICACY IN PATIENTS WITH HORMONE-RESPONSIVE EARLY BREAST CANCER (BC) IN THE AUSTRIAN BREAST AND COLORECTAL CANCER STUDY GROUP (ABCSG)-12 TRIAL
    Gnant, M.
    Mlineritsch, B.
    Schippinger, W.
    Luschin-Ebengreuth, G.
    Steger, G. G.
    Bjelic-Radisic, V.
    Jakesz, R.
    Kubista, E.
    Marth, C.
    Greil, R.
    [J]. ANNALS OF ONCOLOGY, 2009, 20 : 30 - 30
  • [6] Zoledronic acid combined with adjuvant endocrine therapy of tamoxifen versus anastrozol plus ovarian function suppression in premenopausal early breast cancer: final analysis of the Austrian Breast and Colorectal Cancer Study Group Trial 12
    Gnant, M.
    Mlineritsch, B.
    Stoeger, H.
    Luschin-Ebengreuth, G.
    Knauer, M.
    Moik, M.
    Jakesz, R.
    Seifert, M.
    Taucher, S.
    Bjelic-Radisic, V.
    Balic, M.
    Eidtmann, H.
    Eiermann, W.
    Steger, G.
    Kwasny, W.
    Dubsky, P.
    Selim, U.
    Fitzal, F.
    Hochreiner, G.
    Wette, V.
    Sevelda, P.
    Ploner, F.
    Bartsch, R.
    Fesl, C.
    Greil, R.
    [J]. ANNALS OF ONCOLOGY, 2015, 26 (02) : 313 - 320
  • [7] Cost-effectiveness of zoledronic acid plus endocrine therapy in premenopausal women with early stage breast cancer based on results of the ABCSG-12 study.
    Delea, T. E.
    Taneja, C.
    Sofrygin, O.
    Kaura, S.
    Gnant, M.
    [J]. CANCER RESEARCH, 2009, 69 (02) : 190S - 191S
  • [8] COST-EFFECTIVENESS OF ADDING ZOLEDRONIC ACID TO ENDOCRINE THERAPY IN PREMENOPAUSAL WOMEN WITH HORMONE-RESPONSIVE EARLY BREAST CANCER IN GREECE, BASED ON THE ABCSG-12 STUDY
    Delea, T. E.
    Taneja, C.
    Kaura, S.
    Chatzikou, M.
    Maiadiakis, N.
    Fagoulakis, V
    [J]. VALUE IN HEALTH, 2009, 12 (07) : A270 - A270
  • [9] Adjuvant endocrine therapy plus zoledronic acid in premenopausal women with early-stage breast cancer: 62-month follow-up from the ABCSG-12 randomised trial
    Gnant, Michael
    Mlineritsch, Brigitte
    Stoeger, Herbert
    Luschin-Ebengreuth, Gero
    Heck, Dietmar
    Menzel, Christian
    Jakesz, Raimund
    Seifert, Michael
    Hubalek, Michael
    Pristauz, Gunda
    Bauernhofer, Thomas
    Eidtmann, Holger
    Eiermann, Wolfgang
    Steger, Guenther
    Kwasny, Werner
    Dubsky, Peter
    Hochreiner, Gerhard
    Forsthuber, Ernst-Pius
    Fesl, Christian
    Greil, Richard
    [J]. LANCET ONCOLOGY, 2011, 12 (07): : 631 - 641
  • [10] Influence of Delayed Zoledronic Acid Initiation on Disease-Free Survival in Postmenopausal Women with Endocrine Receptor-Positive Early Breast Cancer Receiving Adjuvant Letrozole: Exploratory Analyses from the ZO-FAST Trial
    Coleman, R.
    De, Boer R.
    Eidtmann, H.
    Neven, P.
    von Minckwitz, G.
    Martin, N.
    Modi, A.
    Bundred, N.
    [J]. CANCER RESEARCH, 2011, 71
123